Used in the treatment and management of hemophilia A, a genetic disorder caused by a deficiency of factor VIII. Efmoroctocog alfa is a recombinant Factor VIII protein, synthesized biologically, that temporarily increases factor VIII levels in the blood to help control and prevent bleeding episodes. Commonly administered intravenously, it supports surgical procedures and manages acute bleeding in both adults and children. Also used for routine prophylaxis to reduce the frequency of bleeding episodes.